Navigation Links
AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
Date:3/2/2010

AMSTERDAM, March 2, 2010 /PRNewswire/ -- Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

The preclinical research phase of the project is funded by the Joint Call initiative of the three Dutch Public Private Partnerships, the BioMedical Materials (BMM) program, the Centre for Translational Molecular Medicine (CTMM) and Top Institute Pharma (TI Pharma), focussing on the interface of the three institutes: Imaging Guided and Targeted Drug Delivery. Fifty percent of the total funding budget of 4.2 million euro is provided by the Dutch government, with the remaining fifty percent being provided by the consortium partners.

Influenza A infections remain a substantial health threat, as revealed by the significant annual influenza A-related morbidity and mortality. Both the preparation for influenza A pandemic and the consequences of such a pandemic when manifested cause substantial socio-economical costs. Protection afforded by traditional influenza A vaccines is mediated in large part by antibodies. In contrast, induction of cytotoxic T cells, the other effector arm of the adaptive immune system is highly inefficient. Notably, efficient induction of cytotoxic T cell responses would be highly attractive, as contrary to the molecular structures recognized by antibodies, the structures recognized by cytotoxic T cells are in large part conserved between different influenza A subtypes.

Based on this notion and the proven protective effect of cytotoxic T cells on influenza A infection in preclinical models, the AmpVacs Vaccine consortium will develop an innovative fully synthetic influenza A vaccine component. To achieve this aim, the consortium will build on in-house technologies developed by the partners. Specifically, the consortium will make use of T cell imaging technology developed by one of the partners for the generation of a database of T cell epitopes. This database will then be utilized for the development and evaluation of a fully synthetic influenza A vaccine component, using specific formulation technology of the partners. Thus, the central aim of the consortium is to develop a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats. Notably, the development of the multiplexed T cell imaging technology for the diagnostics of human immune function that this project will achieve will form a major fringe benefit of the project that will be of broad value for future vaccine design.

About Sanquin Blood Supply Foundation

Sanquin Blood Supply Foundation (with its headquarters in Amsterdam, the Netherlands) is an internationally reputed organization in the field of blood banking and immuno-hematological research. Sanquin has a track record in bringing therapeutic proteins, and in vitro diagnostic and research products to the market and is successfully distributing a substantial product portfolio covering these fields on the international market.

About the Netherlands Cancer Institute

The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), of which Queen Beatrix of the Netherlands is patron, consists of a scientific research laboratory and a specialized clinic. Since its foundation in 1913, its primary objective has been to combat cancer by combining patient care, research and education. The staff's ambition is to make a real contribution to solving the problem of cancer thanks to the unique interaction between scientific research and clinical application that is woven into the fabric of the organization.

About the Netherlands Vaccine Institute

The Netherlands Vaccine Institute (NVI) in Bilthoven reflects more than 100 years of extensive knowledge and experience gained through research and production of vaccines. The NVI is an agency responsible to the Ministry of Health, Welfare and Sport. It guarantees the supply of vaccines necessary to protect the Dutch population against infectious diseases. The vaccines are used both in the regular National Immunisation Programmes and for emergency vaccination campaigns.

SOURCE Sanquin Blood Supply Foundation

Back to top
'/>"/>
SOURCE Sanquin Blood Supply Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
4. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
5. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
6. Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
7. Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity
8. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
9. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
10. Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
11. D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/9/2017)... , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September ... Washington, D.C. offering free MRI brain scans to the public.Where:  ... will be parked at 501 K Street NW, Washington, D.C.What:BTF brings its ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology:
(Date:9/22/2017)... San Francisco, CA (PRWEB) , ... September 22, ... ... a way to help you brush more effectively even on the go. Their ... diseases like gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving ... lost, have value to God. “Letters From Home” is the creation of published author, ... the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on ...
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to preserve fertility and create life. Although frozen embryos have a slight statistical ... , “Egg freezing is a wonderful opportunity for women undergoing medical treatment ...
(Date:9/21/2017)... ... 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a stylistic ... from up to two layers of subject matter along with fully customizable backdrop animation, ... Final Cut Pro X. , With ProSlideshow Portrait each user are given the ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... get things wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers ...
Breaking Medicine News(10 mins):